Filing Flows › Acadia Pharmaceuticals (ACAD) › Q2 2025
Acadia Pharmaceuticals (ACAD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Acadia Pharmaceuticals (ACAD) reported revenue of $265M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +8% from the quarter before. Operating margin was 12.2%, net earnings $26.7M (10.1% of revenue).
Acadia Pharmaceuticals, Q2 2025: revenue $265M (+9% year over year), operating margin 12.2%, net earnings $26.7M, operating cash flow $64.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $265M | +8% | +9% |
| Operating profit | $32.4M | +68% | +6% |
| Net earnings | $26.7M | +40% | -20% |
| Operating cash flow | $64.0M | +215% | +156% |
| Free cash flow | $63.7M | +213% | — |
What changed
Revenue was $264.6M in Q2 2025, up 9% year over year and up 8% from the previous quarter.
Operating profit was $32.4M, a 12.2% margin (down 0.3 points year over year). Of the extra revenue versus a year earlier, 9% reached operating profit, below the 13% margin then. Total costs grew 10% against revenue growth of 9%. The fastest-growing cost line was SG&A (+14%). Net earnings were $26.7M, down 20% year over year. The effective tax rate was 33.7%.
Operating cash flow was $64.0M (up 156% year over year), 240% of net earnings. Non-cash charges added back $2.9M of depreciation and amortization and $14.3M of share-based compensation. Working capital and other items added $20.0M. Capital expenditures of $297K left free cash flow of $63.7M.
Questions
What was Acadia Pharmaceuticals' revenue in the second quarter 2025?
Acadia Pharmaceuticals (ACAD) reported revenue of $265M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +8% from the quarter before.
Was Acadia Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $32.4M (12.2% of revenue) and net earnings $26.7M.